Introduction
The identification of the human T cell lymphotropic virus type III/lymphadenopathy associated virus (HTLV-III/LAV)'2and the development of sensitive and specific assays for detecting antibody to it (anti-HTLV-III/LAV) have permitted studies to define the prevalence of viral infection in groups at risk for the acquired immune deficiency syndrome (AIDS). We describe the results of a collaborative survey undertaken at the end of 1984 to define the prevalence of HTLV-III/LAV and HTLV-I infections among recipients in Britain of various blood products at that time.
Patients and methods
We examined 1040 serum immunosorbent assay modification of a previously described radioimmunoassay which was considered free from interference through freezethawing,3 heat inactivation of serum, and the presence of antilymphocyte antibodies. Serum samples from patients with haemophilia A were also tested for antibody to HTLV-I by a competitive enzyme linked immunosorbent assay modification of the method previously described.4
Patients were grouped into those with haemophilia A (factor VIII deficiency) and those with haemophilia B (factor IX deficiency). Thirty two patients, including those with other factor deficiencies, von Willebrand's disease, or acquired clotting deficiencies, made up a small miscellaneous group. Patients with inherited factor VIII deficiency were divided according to their treatment since 1978 into those who had received any commercial factor VIII concentrate and those receiving British prepared factor VIII concentrate only.
Results and discussion
In 1984 the greatest burden of infection was borne by patients who had received commercial factor VIII concentrate in the preceding five years (table I) . Roughly two thirds of such patients were seropositive. By contrast, only 18 patients among 166 who had received British factor VIII exclusively were seropositive. At the time of study 15 of these cases were accounted for by infections arising in a group of 33 Scottish haemophiliacs given a uniquely infectious batch of British concentrate.3 Outside this group only three infections appeared to have occurred by 1984 in the remaining 132 patients exclusively treated with British factor VIII concentrate. These data suggest that up to 1984 the risk of acquiring infection from using native British concentrates was present but low, reflecting the low prevalence of HTLV-III/LAV infected donors among the voluntary donor panels in the United Kingdom. Since it was difficult to exclude occasional rare exposure to commercial concentrate-for example, some patients shared concentrates with visiting affected brothers-it is possible that these infections may not necessarily have arisen from the British concentrates.
The contrast in the prevalence of infection between recipients of volunteer and of commercial donor products was shown by the 1984 prevalence data and further emphasised by the yearly point prevalence figures for seropositivity in haemophiliacs (table II) . Seroconversion began in this group as early as 1980 and continued through 1981 and 1982-a finding previously noted by Professor L Luzzatto,`a whose data are included. HTLV-III/LAV infections have only recently become established in British homosexuals67 and it is therefore not surprising that the emergence of infection in those patients receiving commercial concentrate paralleled more nearly seropositivity for drug addicts and homosexuals in the United States. If this proves to be the case, then the outcome of seropositivity in haemophiliacs may perhaps be less grave than has been suggested.8 Besides HTLV-III/LAV, it was known that HTLV-I and HTLV-II were also prevalent in the subjects at risk for AIDS4 and might be represented among the commercial donors.
There was no evidence of HTLV-I infection in any patient with the exception of a single Japanese, who was seronegative for HTLV-III/LAV (table III) . This finding accords with previous studies, 9 showing that HTLV-I was not transmitted by blood products prepared from pooled plasma. The failure of HTLV-I to transmit was also likely to be due to a relatively low prevalence of infected donors and the presence of high concentrations of neutralising antibody in plasma from any infected donor.'0 The prevalence of HTLV-III/LAV infection remained comparatively unchanged from 1982 onwards. This may have been due to the exclusion of high risk subjects from the commercial donor panels though this seems unlikely in view of the seroconversions documented in 1983 and 1984. There are two alternative explanations: either these highly exposed but seronegative patients represented people relatively insusceptible to infection with HTLV-III/LAV or they represented infected people in whom the virus was truly latent and unexpressed. Ifthe second were true the virus might become actively expressed at any later time and would be associated with late seroconversion and the usual clinical sequelae to infection. We still have a great deal to learn with this new viral infection and only the passage of time and careful study may turn speculation into fact.
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Introduction
Corticosteroids are now generally accepted to be of value in the management of patients admitted to hospital with acute severe asthma.' Their value for patients not admitted to hospital is less clear. These patients have by implication less severe asthma at the time of presentation, and it might be argued that improvement would occur just as quickly with corticosteroid treatment as without it. We conducted a study to examine whether a three day course of prednisolone speeded recovery in children with an acute episode of asthma managed at home. We assessed both symptomatic improvement and improvement in airways obstruction as measured by changes in peak expiratory flow rate (PEFR).
Patients and methods
Children with asthma who attended the paediatric chest clinic were eligible for admission to the study provided they could use a peak flow meter.
